FENTON, Mich.--(BUSINESS WIRE)--March 4, 2005-- ZANN Corp. (OTCBB:ZANN) announced today that they now have initial success in developing effective specific antibodies against one major species of bacteria found in human blood. The commercial value of this achievement has significant upside potential both in medical diagnostics and gene therapy products. According to Luther E. Lindner, MD, PhD, Chief Medical Officer, "ZANN Corp.'s scientists (formerly Pathobiotek) have been culturing and characterizing a set of bacteria that they found to be generally present in the human bloodstream. Their characterization to date has been reported at five (ASM, Pathologists and Blood) scientific/medical meetings. One species is now in continuous culture and another major species is nearly in continuous culture. As the culture system improves, their properties, particularly their ability to persist in the bloodstream, have attractive potential for their development as a platform for some types of gene therapy. ?? "We have been collaborating with another company for the development of our monoclonal antibodies directed against two major species of bacteria. The role of these bacteria in disease is still not entirely clear, but their continuous presence in the human bloodstream gives them the opportunity to be associated with still-unexplained disease processes. Previous small-scale studies have found an increased level of these bacteria in the active stages of several conditions, such as classical autoimmune diseases, multiple sclerosis, and chronic fatigue syndrome. The production of these monoclonal antibodies will allow development of more practical and specific quantitative testing and should help establish links with disease." ZANN Corp. intends to establish collaborations to develop and market specific tests based on these antibodies. The market for these tests remains to be established, but at least one million Americans are diagnosed with one of the conditions where elevated levels of these bacteria have been seen. It is expected that a specific quantitative test will have value for evaluating disease activity in this population. As the testing system is developed and other studies of pathogenicity are done, it is likely that additional disease associations will be found.
ABOUT ZANN CORP.
ZANN Corp. manages our five main scalable technologies and systems - nutraceuticals, niche market vehicle sales, financial services, antibodies and gene therapy for potentially harmful bacterium while managing performance. Each technology group is a profit center measured by its contribution to overall significant growth that enables building a company with a diverse range of high quality, high value products and services for niche markets where we can excel. For additional information please visit the corporate website at: www.zanncorp.com Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
KEYWORD: NORTH AMERICA MICHIGAN UNITED STATES INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS HOSPITALS RESEARCH & SCIENCE SOURCE: ZANN Corp.
-------------------- Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game. Posts: 605 | From: Ontario, Canada | Registered: Feb 2005
| IP: Logged |
posted
It could run nicely if it could break through the wall of mm's on the ask at .0006
Posts: 2049 | From: Jax,FL,USA | Registered: Nov 2003
| IP: Logged |
posted
this is huge news..already they were taking about moving to Amex in 2006
Press Release Source: ZANN Corp.
ZANN Corp. Reports on Antibody Development Success Friday March 4, 9:49 am ET
FENTON, Mich.--(BUSINESS WIRE)--March 4, 2005--ZANN Corp. (OTCBB:ZANN - News) announced today that they now have initial success in developing effective specific antibodies against one major species of bacteria found in human blood. The commercial value of this achievement has significant upside potential both in medical diagnostics and gene therapy products. According to Luther E. Lindner, MD, PhD, Chief Medical Officer, "ZANN Corp.'s scientists (formerly Pathobiotek) have been culturing and characterizing a set of bacteria that they found to be generally present in the human bloodstream. Their characterization to date has been reported at five (ASM, Pathologists and Blood) scientific/medical meetings. One species is now in continuous culture and another major species is nearly in continuous culture. As the culture system improves, their properties, particularly their ability to persist in the bloodstream, have attractive potential for their development as a platform for some types of gene therapy.
"We have been collaborating with another company for the development of our monoclonal antibodies directed against two major species of bacteria. The role of these bacteria in disease is still not entirely clear, but their continuous presence in the human bloodstream gives them the opportunity to be associated with still-unexplained disease processes. Previous small-scale studies have found an increased level of these bacteria in the active stages of several conditions, such as classical autoimmune diseases, multiple sclerosis, and chronic fatigue syndrome. The production of these monoclonal antibodies will allow development of more practical and specific quantitative testing and should help establish links with disease."
ZANN Corp. intends to establish collaborations to develop and market specific tests based on these antibodies. The market for these tests remains to be established, but at least one million Americans are diagnosed with one of the conditions where elevated levels of these bacteria have been seen. It is expected that a specific quantitative test will have value for evaluating disease activity in this population. As the testing system is developed and other studies of pathogenicity are done, it is likely that additional disease associations will be found.
ABOUT ZANN CORP.
ZANN Corp. manages our five main scalable technologies and systems - nutraceuticals, niche market vehicle sales, financial services, antibodies and gene therapy for potentially harmful bacterium while managing performance. Each technology group is a profit center measured by its contribution to overall significant growth that enables building a company with a diverse range of high quality, high value products and services for niche markets where we can excel.
For additional information please visit the corporate website at: www.zanncorp.com
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
posted
365m volume..this will not stay under .0010 too long..watch this moving to .0025-.0030 range soon by close or tomorrow
Posts: 714 | From: Boston, MA USA | Registered: Aug 2004
| IP: Logged |
posted
NITE holding tight at .0005 , but tons of buys coming in at that price , won't be able to keep it there for long .
Posts: 734 | From: Nassau County | Registered: Jan 2005
| IP: Logged |
posted
Alot of weak hands jumped ship at .0004 and .0005 , may regret it later .
Posts: 734 | From: Nassau County | Registered: Jan 2005
| IP: Logged |
posted
It might not move much today but weekend news would make this one fly Monday:)
-------------------- Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game. Posts: 605 | From: Ontario, Canada | Registered: Feb 2005
| IP: Logged |
posted
4 MM's waiting at .0006 . By the way , some of these sells are for only 15,000 , 200 , manipulation ?
Posts: 734 | From: Nassau County | Registered: Jan 2005
| IP: Logged |
posted
.0004 ..buy this now cheap..this is headed way way up with 400m volume already
Posts: 714 | From: Boston, MA USA | Registered: Aug 2004
| IP: Logged |
-------------------- Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game. Posts: 605 | From: Ontario, Canada | Registered: Feb 2005
| IP: Logged |
quote:Originally posted by GT500: I agree, I waited to get in @ 0.0004
It'll go up!
Good job...I had a little extra money and added to my position at .0005...didn't think it'd hit .0004 again.
Posts: 2049 | From: Jax,FL,USA | Registered: Nov 2003
| IP: Logged |
posted
MM's are caught with short position..they did not expect this big news..too much buying pressure at .0004..they will be forced to increase the bids soon..get in cheap at .0004
Posts: 714 | From: Boston, MA USA | Registered: Aug 2004
| IP: Logged |
posted
If you missed a chance to get in back at .0001-.0003 get in now
-------------------- Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game. Posts: 605 | From: Ontario, Canada | Registered: Feb 2005
| IP: Logged |
posted
two months ago they had a 900 for 1 reverse split...todays volume is 400 million...im reading that their "authorized" share amount is 900 million...ill be danged if i can figure out their o/s or float...im seeing some really silly low numbers but i would think after a 900/1 r/s...the numbers should be low....anybody know whats going on with o/s or float...im in this one just for the heck of it but what the hey are the real share numbers??
-------------------- 4,311 heads are better than one...unless that one is a market maker Posts: 271 | From: california | Registered: Jan 2005
| IP: Logged |
posted
Don't think too many peep care right now , jus want to go along for this little ride .
Posts: 734 | From: Nassau County | Registered: Jan 2005
| IP: Logged |
posted
Come on SCHB and NITE , can't keep this thing at .0004 much longer , way too many buys now .
Posts: 734 | From: Nassau County | Registered: Jan 2005
| IP: Logged |
posted
We just need to bring the ask back to .0005
-------------------- Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game. Posts: 605 | From: Ontario, Canada | Registered: Feb 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
